Damora Therapeutics, Inc. (DMRA) Stock Forecast Nov. 3, 2026
Analysis updated on Nov. 3, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Damora Therapeutics, Inc. (DMRA) stock forecast summary
Our AI scores Damora Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Damora Therapeutics, Inc. is a small-cap company with a market capitalization of $1.33B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For DMRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -25.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -10.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, DMRA included.
DMRA price chart and AI forecast
How DMRA ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Damora Therapeutics, Inc. (DMRA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | DMRA | Rank |
|---|---|---|
| Market Cap | $1.33B | 60/60 |
| P/E Ratio | 2.66x | 32/33 |
| P/B Ratio | 2.58x | 39/42 |
| EPS | $8.11 | – |
| Book Value/Share | $8.36 | – |
Profitability & Margins
| Metric | DMRA | Rank |
|---|---|---|
| ROIC | -52.4% | 39/44 |
| Tax Rate | -0.1% | – |
Financial Health
| Metric | DMRA | Rank |
|---|---|---|
| Current Ratio | 19.73x | 6/58 |
| D/E Ratio | 0.05x | 41/47 |
| Financial Leverage | 1.05x | 41/47 |
| Interest Coverage | -8.6x | 25/35 |
| Working Capital | $516M | 41/58 |
Cash Flow
| Metric | DMRA | Rank |
|---|---|---|
| Operating Cash Flow | -$45M | 40/59 |
Income Statement
| Metric | DMRA | Rank |
|---|---|---|
| Operating Income | -$271M | 39/51 |
| R&D Expense | $74M | 55/58 |
Dividend & Shareholder Information
| Metric | DMRA | Rank |
|---|---|---|
| Shares Outstanding | 62M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $544M | 99.8% of assets |
| Cash & Short-term Investments | $541M | 99.3% of assets |
| Total Liabilities | $28M | 5.1% of assets |
| Short-term Debt | $24M | 4.4% of assets |
DMRA quarterly financials and insider trading
Damora Therapeutics, Inc. (DMRA) industry peers
Companies classified under the same SEC industry code as Damora Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| DMRA Damora Therapeutics, Inc. | $1.33B | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $651.32B | |
| ABBV Abbvie Inc. | $521.11B | |
| MRK Merck & Co., Inc. | $366.03B | |
| NVS Novartis Ag | $308.20B | |
| AZN Astrazeneca Plc | $289.20B | |
| ABT Abbott Laboratories | $191.55B | |
| NVO Novo Nordisk A S | $177.76B | |
| PFE Pfizer Inc | $174.81B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $136.87B | |
| BMY Bristol Myers Squibb Co | $128.73B | |
| SNY Sanofi | $106.33B | |
| GSK Gsk Plc | $99.12B | |
| REGN Regeneron Pharmaceuticals, Inc. | $98.97B | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | |
| TEVA Teva Pharmaceutical Industries Ltd | $47.43B | |
| ONC Beone Medicines Ltd. | $41.07B | |
| GMAB Genmab A/S | $36.34B | |
| ZTS Zoetis Inc. | $34.37B | |
| RPRX Royalty Pharma Plc | $28.77B | |
| ROIV Roivant Sciences Ltd. | $25.92B | |
| UTHR United Therapeutics Corp | $25.57B | |
| INSM Insmed Inc | $23.87B | |
| VTRS Viatris Inc | $21.44B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.14B | |
| ASND Ascendis Pharma A/S | $16.35B | |
| BBIO Bridgebio Pharma, Inc. | $14.66B | |
| JAZZ Jazz Pharmaceuticals Plc | $13.92B | |
| ELAN Elanco Animal Health Inc | $12.04B | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | |
| SMMT Summit Therapeutics Inc. | $11.81B | |
| BMRN Biomarin Pharmaceutical Inc | $11.12B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.96B | |
| TGTX Tg Therapeutics, Inc. | $9.22B | |
| PTGX Protagonist Therapeutics, Inc | $9.02B | |
| CORT Corcept Therapeutics Inc | $8.70B | |
| CYTK Cytokinetics Inc | $8.62B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.54B | |
| SYRE Spyre Therapeutics, Inc. | $8.42B | |
| PRAX Praxis Precision Medicines, Inc. | $7.65B | |
| ALKS Alkermes Plc. | $7.53B | |
| ABVX Abivax S.A. | $7.43B | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | |
| AXSM Axsome Therapeutics, Inc. | $7.12B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.09B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.53B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | |
| ORKA Oruka Therapeutics, Inc. | $6.32B | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | |
| BLTE Belite Bio, Inc | $6.05B | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.61B | |
| MANE Veradermics, Inc | $5.41B | |
| COGT Cogent Biosciences, Inc. | $5.16B | |
| PTCT Ptc Therapeutics, Inc. | $5.08B | |
| ERAS Erasca, Inc. | $4.91B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.60B | |
| TVTX Travere Therapeutics, Inc. | $4.41B | |
| INDV Indivior Pharmaceuticals, Inc. | $4.17B | |
| EWTX Edgewise Therapeutics, Inc. | $4.14B |
Where DMRA sits on the market map
Damora Therapeutics, Inc. (DMRA) stock news
Loading...
Damora Therapeutics, Inc. (DMRA) stock forecast FAQ
What is the Damora Therapeutics, Inc. (DMRA) stock forecast?
Our AI scores Damora Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Damora Therapeutics, Inc. stock predictions?
For DMRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -25.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -10.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Damora Therapeutics, Inc. forecasts updated?
Damora Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 3, 2026.
Which companies are Damora Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, DMRA included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.